Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It’s Apples and Oranges-Reference-Cited by-同舟云学术

Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It’s Apples and Oranges

Published:2022-08-25 Issue:8 Volume:3 Page:1442-1444
ISSN:2641-7650
Container-title:Kidney360
language:en
Short-container-title:Kidney360

Author:

Leon Silvia J.,Tangri Navdeep

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference16 articles.

1. Chronic kidney disease;Levey;Lancet,2012

2. Hyperkalemia and its association with mortality, cardiovascular events, hospitalizations, and intensive care unit admissions in a population-based retrospective cohort;Hougen;Kidney Int Rep,2021

3. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors;Weir;Clin J Am Soc Nephrol,2010

4. The use of renin-angiotensin system inhibitors in patients with chronic kidney disease;Leon;Can J Cardiol,2019

5. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease;Levin

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort;Kidney360;2024-05-28

2. Randomised, blinded, cross-over evaluation of the palatability of and preference for different potassium binders in participants with chronic hyperkalaemia in the USA, Canada and Europe: the APPETIZE study;BMJ Open;2024-02

3. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO‐DKD and FIDELIO‐DKD;Diabetes, Obesity and Metabolism;2023-11-30

4. Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone;Expert Review of Clinical Pharmacology;2023-05-23

5. Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review;Terapevticheskii arkhiv;2023-04-26